Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortEGFR tablet for lung cancers with EGFR mutations.First-generation EGFR tablet for mutated lung cancer.
Body systemCancerCancer
Drug classTyrosine kinase inhibitorsTyrosine kinase inhibitors
SupplyPrescription onlyWHO essential medicinePrescription onlyWHO essential medicine
Main usesEGFR-mutated non-small-cell lung cancer, Pancreatic cancer (with gemcitabine)EGFR-mutated non-small-cell lung cancer
How it worksBlocks a growth signal in EGFR-mutated lung cancer.Blocks a growth signal in EGFR-mutated lung cancer.
Starts workingDepends on the cancer and regimenDepends on the cancer and regimen
Half-lifeAbout 36 hoursAbout 48 hours
Typical adult doseDosed by your cancer team according to the treatment protocol.Dosed by your cancer team according to the treatment protocol.
FormsTabletTablet
Common side effectsAcne-like rash, Diarrhoea, Dry skin, Loss of appetite, TirednessAcne-like rash, Diarrhoea, Dry skin, Nausea, Tiredness
Serious side effectsLung inflammation, Liver failure, Bowel perforation, Eye problemsLung inflammation, Liver injury, Bowel perforation
Don't take ifPregnancy; Severe liver impairmentPregnancy; Severe liver impairment
AlcoholBest to limit. Alcohol may add to liver strain.Best to limit. Alcohol may add to liver strain.
PregnancyUsually avoidedAvoid.Usually avoidedAvoid.
BreastfeedingUsually avoidedAvoid.Usually avoidedAvoid.
In use since——
Brand namesUnited States: TarcevaUnited Kingdom: TarcevaIndia: Tarceva, Erlonib, Erlotinib (generic)United States: IressaUnited Kingdom: IressaIndia: Iressa, Gefitinib (generic)
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H
ATC codeL01EB02L01EB01

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker